AST-302 / Aston Sci., EpiThany, University of Washington - LARVOL DELTA

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: University of Washington | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CD4 • ER • HER-2 • PGR

MCC-19117: Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov) - P2 | N=119 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2027 ➔ Dec 2027 | Trial primary completion date: Mar 2026 ➔ Dec 2025

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Male Breast Cancer • Oncology • Solid Tumor

MCC-19117: Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov) - P2 | N=119 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Male Breast Cancer • Oncology • Solid Tumor

WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: University of Washington | Active, not recruiting ➔ Completed | N=24 ➔ 32

Enrollment change • Metastases • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • HER-2